TP53 and small cell lung carcinoma: The results revealed that 74.6% of Chinese SCLC patients harbored both TP53 and RB1 mutation, which was lower than that reported by an international group from Europe and US which we speculated that the patients were mainly the Western population (90.9%, P = 0.007) (Figure 2A).11 The data from previous study were calculated based on oncoprint results in the literature: of the 110 samples, 100 had both TP53 and RB1 mutations.